CA3059283A1 - C5-anilinoquinazoline compounds and their use in treating cancer - Google Patents
C5-anilinoquinazoline compounds and their use in treating cancer Download PDFInfo
- Publication number
- CA3059283A1 CA3059283A1 CA3059283A CA3059283A CA3059283A1 CA 3059283 A1 CA3059283 A1 CA 3059283A1 CA 3059283 A CA3059283 A CA 3059283A CA 3059283 A CA3059283 A CA 3059283A CA 3059283 A1 CA3059283 A1 CA 3059283A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- triazol
- amino
- acetamide
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490859P | 2017-04-27 | 2017-04-27 | |
| US62/490,859 | 2017-04-27 | ||
| PCT/EP2018/060798 WO2018197642A1 (en) | 2017-04-27 | 2018-04-26 | C5-anilinoquinazoline compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3059283A1 true CA3059283A1 (en) | 2018-11-01 |
Family
ID=62091877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3059283A Pending CA3059283A1 (en) | 2017-04-27 | 2018-04-26 | C5-anilinoquinazoline compounds and their use in treating cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10273227B2 (https=) |
| EP (1) | EP3615522B1 (https=) |
| JP (1) | JP7128204B2 (https=) |
| KR (1) | KR102603153B1 (https=) |
| CN (1) | CN110573505B (https=) |
| AR (1) | AR111494A1 (https=) |
| AU (1) | AU2018259078B2 (https=) |
| CA (1) | CA3059283A1 (https=) |
| ES (1) | ES2888298T3 (https=) |
| MX (1) | MX389244B (https=) |
| RU (1) | RU2769694C2 (https=) |
| TW (1) | TWI774758B (https=) |
| WO (1) | WO2018197642A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7128204B2 (ja) * | 2017-04-27 | 2022-08-30 | アストラゼネカ・アクチエボラーグ | Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用 |
| EP3867280A4 (en) * | 2018-10-18 | 2022-11-09 | Sinomab Bioscience Limited | METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| MX2022013797A (es) | 2020-05-08 | 2022-11-30 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
| WO2022040341A1 (en) * | 2020-08-20 | 2022-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Abscopal therapy for cancer |
| CN116782933A (zh) | 2020-09-10 | 2023-09-19 | 健玛保 | 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| KR20230066040A (ko) | 2020-09-10 | 2023-05-12 | 젠맵 에이/에스 | 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체 |
| CA3189883A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| CA3190376A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| TW202345831A (zh) * | 2021-12-09 | 2023-12-01 | 美商迪賽孚爾製藥有限公司 | Ｋｉｔ激酶抑制劑及其使用方法 |
| US20250275978A1 (en) * | 2024-03-04 | 2025-09-04 | Cardiff Oncology, Inc. | Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| CA2384291A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
| DK1382604T3 (da) | 2001-04-27 | 2006-04-18 | Kirin Brewery | Quinolinderivater med en azolylgruppe og quinazolinderivater |
| TW200505452A (en) * | 2003-06-17 | 2005-02-16 | Astrazeneca Ab | Chemical compounds |
| EP1684762A4 (en) * | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| BRPI0516093A (pt) | 2004-10-12 | 2008-08-19 | Astrazeneca Ab | derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20070106549A1 (en) | 2005-11-04 | 2007-05-10 | Stocking Christine A | Turnkey aviation budget management |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2008089310A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of obesity |
| US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| TWI377944B (en) * | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| AU2009246263B2 (en) | 2008-05-14 | 2014-08-21 | Amgen Inc. | Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CN102532042A (zh) * | 2010-12-30 | 2012-07-04 | 上海医药工业研究院 | 一种芳基脲类化合物、其中间体及其应用 |
| WO2012155339A1 (zh) * | 2011-05-17 | 2012-11-22 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| CN103254142B (zh) | 2013-04-26 | 2015-10-28 | 浙江工业大学 | 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| CN104130200B (zh) | 2014-07-01 | 2016-04-20 | 中山大学 | 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用 |
| JP7128204B2 (ja) * | 2017-04-27 | 2022-08-30 | アストラゼネカ・アクチエボラーグ | Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用 |
| WO2018197643A1 (en) | 2017-04-27 | 2018-11-01 | Astrazeneca Ab | Phenoxyquinazoline compounds and their use in treating cancer |
-
2018
- 2018-04-26 JP JP2019557764A patent/JP7128204B2/ja active Active
- 2018-04-26 KR KR1020197034070A patent/KR102603153B1/ko active Active
- 2018-04-26 CN CN201880027620.0A patent/CN110573505B/zh active Active
- 2018-04-26 CA CA3059283A patent/CA3059283A1/en active Pending
- 2018-04-26 EP EP18721348.3A patent/EP3615522B1/en active Active
- 2018-04-26 MX MX2019012847A patent/MX389244B/es unknown
- 2018-04-26 US US15/963,122 patent/US10273227B2/en active Active
- 2018-04-26 TW TW107114297A patent/TWI774758B/zh active
- 2018-04-26 AU AU2018259078A patent/AU2018259078B2/en active Active
- 2018-04-26 ES ES18721348T patent/ES2888298T3/es active Active
- 2018-04-26 RU RU2019136279A patent/RU2769694C2/ru active
- 2018-04-26 WO PCT/EP2018/060798 patent/WO2018197642A1/en not_active Ceased
- 2018-04-27 AR ARP180101102A patent/AR111494A1/es active IP Right Grant
-
2019
- 2019-03-05 US US16/292,817 patent/US10829479B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180312490A1 (en) | 2018-11-01 |
| MX389244B (es) | 2025-03-20 |
| CN110573505B (zh) | 2023-04-11 |
| BR112019022229A2 (pt) | 2020-05-12 |
| JP7128204B2 (ja) | 2022-08-30 |
| RU2019136279A (ru) | 2021-05-27 |
| RU2019136279A3 (https=) | 2021-05-31 |
| AR111494A1 (es) | 2019-07-17 |
| ES2888298T3 (es) | 2022-01-03 |
| AU2018259078A1 (en) | 2019-10-17 |
| JP2020517677A (ja) | 2020-06-18 |
| RU2769694C2 (ru) | 2022-04-05 |
| EP3615522A1 (en) | 2020-03-04 |
| TWI774758B (zh) | 2022-08-21 |
| EP3615522B1 (en) | 2021-08-04 |
| MX2019012847A (es) | 2022-01-07 |
| TW201904960A (zh) | 2019-02-01 |
| AU2018259078B2 (en) | 2021-10-07 |
| US20190263787A1 (en) | 2019-08-29 |
| US10273227B2 (en) | 2019-04-30 |
| WO2018197642A1 (en) | 2018-11-01 |
| US10829479B2 (en) | 2020-11-10 |
| KR20190141203A (ko) | 2019-12-23 |
| CN110573505A (zh) | 2019-12-13 |
| KR102603153B1 (ko) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018259078B2 (en) | C5-anilinoquinazoline compounds and their use in treating cancer | |
| CN114846006B (zh) | 杂环化合物及其制备方法和用途 | |
| RU2656597C2 (ru) | Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста | |
| AU2016323399B2 (en) | 8-(6-(3-(amino)propoxy)-3-pyridyl)-1 -isopropyl-imidazo(4,5-c)quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (ATM) kinase for the treatment of cancer | |
| JP2019518776A (ja) | Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶 | |
| KR20170005875A (ko) | 1,3,4-티아디아졸 화합물 및 암의 치료에서의 그의 용도 | |
| CN112334460A (zh) | 联芳基醚型喹唑啉衍生物 | |
| EP3615526B1 (en) | Phenoxyquinazoline compounds and their use in treating cancer | |
| JP2024520920A (ja) | イミダゾリジノン類化合物の多形体、調製方法及びその使用 | |
| BR112019022229B1 (pt) | Compostos de anilinoquinazolina c5, composição farmacêutica e uso dos compostos no tratamento do câncer | |
| AU2016302748A1 (en) | 4-(3-pyrazolylamino)-benzimidazole compounds and their use as JAK1 inhibitors | |
| KR20220159457A (ko) | Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도 | |
| TW202342041A (zh) | 一種藥物組合物及所含活性成分化合物的製備方法 | |
| HK1216315B (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230131 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240820 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250108 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250403 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250403 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250415 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250415 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251014 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251014 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20251224 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260227 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260402 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260402 |